Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5875_Библиотеки_им_академика_М_И_Перельмана

3DP has received signicant attention from the pharmaceutical industry over the past ten years owing to its rapid production, affordable price, and versatility in pharmaceut­ical formulations, thus enabling patients to obtain more effective and safer medication. In the pharmaceutical sector, quality control is a fundamental and crucial activity that ensures high- quality pharmaceutical products. The primary objective is to ensure that the product is safe, efcient, consistent, and reproducible throughout the entire manu­facturing procedure. So it is critical to improve 3D printing quality since low standards could discourage consumers from buying 3D- printed products. Conventional QC techniques that have become prevalent in large- scale manufacturing represent the end­product testing paradigm; such approaches are generally destructive and inappropriate for the 3DP. This demands the development of a non- destructive PAT that requires little to no sample preparation and retains the integrity of the nished product. PAT is currently gaining recognition in research as a QC technique that allows the monitoring of the production process by offering real- time evaluation and management of critical process parameters and previously established CQA. Non- destructive techniques like 3D- DIC, photogrammetry techniques, NIR, RS, and hyper imaging are employed to reduce manufacturing oversights, material waste, variations, and imperfections in the 3DP process, as well as to enhance product quality during the manufacturing process. QC techniques and regulatory strategies like GMP at every stage of manufacture are crucial in enhancing the quality of 3DP formulations.